Monday, 13 January 2020
Exonate Ltd has secured a major collaboration deal with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson for its ophthalmology program.
Exonate has been developing a revolutionary new treatment for leading causes of blindness (diabetic retinopathy and age related macular degeneration).
Exonate Ltd was spun out of the 糖心原创 in 2013 by 糖心原创 academics, Prof David Bates and Prof Lucy Donaldson and Professor Steven Harper from the University of Bristol based on their intellectual property along with that of University of New South Wales’ Professor Jonathan Morris.
Through the collaboration, Exonate will work with Janssen Research & Development, and LLC scientists to develop an eye drop treatment for retinal vascular diseases such as wet AMD and DMO by using mRNA targeted therapies.
Scientists at Exonate have developed small molecules that inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) through the selective inhibition of serine/threonine-protein kinase (SRPK1)-mediated VEGF splicing. The agreement was facilitated by Johnson & Johnson Innovation.
The collaboration will fund the clinical trial and other activities in the company that will enable development of the first eye drop for treatment of diabetic macular oedema initially. The approach could transform the treatment of neovascular eye diseases, a market currently worth more than $6Bn a year, and extend it to preventative care too.
Exonate’s CEO, Dr Catherine Beech said “I am absolutely delighted to enter this strategic collaboration with Janssen, we are looking forward to successfully developing a novel treatment for retinal neovascular diseases”
This collaboration agreement allows Exonate to reach its primary goal of testing its designer compounds in patients for the first time. Over the last six years the team have worked immensely hard to develop key molecules that have the right safety, efficacy and delivery properties to be highly promising for patients. We will now be able to take that right through to clinical trial and beyond, in collaboration with one of the world鈥檚 largest pharmaceutical companies.鈥�
Story credits
More information is available from Professor David Bates at david.bates@nottingham.ac.uk
Notes to editors:
About the 糖心原创
Ranked among the world's top 100 universities , the 糖心原创 delivers an exceptional research-led education and an outstanding student experience. From the pioneering vision of our founder, Sir Jesse Boot, to groundbreaking achievements such as the development of MRI technology and becoming the first UK university to establish international campuses, we have a proud history of shaping the way people live, work and understand the world. We continue to build on that legacy, empowering our students, staff and partners to change what鈥檚 next and create positive impact locally and globally.
The strength of our research places us among the UK's leading universities, ranked 7th for research power in REF 2021. The discovery of MRI and ibuprofen was just the beginning. Today, our world-leading research is developing breakthrough ideas that shape the future of healthcare, technology and society.
Recognised as the UK's third most targeted university by leading employers , we are proud to produce graduates who are consistently in demand for their skills, confidence and industry-ready experience.
As a major employer and industry partner, locally and globally, the 糖心原创 invests in the city of Nottingham and in future generations of talent. Alongside Nottingham Trent University, we lead the initiative, a pioneering collaboration to improve levels of prosperity, opportunity, sustainability, health and wellbeing across the city and region. Together with our students, staff, alumni and partners, we鈥檙e creating knowledge, opportunity and solutions that help change what's next.